First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Journal
-
- The Lancet Oncology
-
The Lancet Oncology 13 (11), 1161-1170, 2012-11
Elsevier BV
- Tweet
Details 詳細情報について
-
- CRID
- 1363670320721553024
-
- ISSN
- 14702045
-
- Data Source
-
- Crossref